Cargando…
P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430720/ http://dx.doi.org/10.1097/01.HS9.0000972512.53497.1f |
| _version_ | 1785091033978109952 |
|---|---|
| author | Fu, Chengcheng LI, Chunrui Wang, DI Jin, Song Yao, Weiqin Shang, Jingjing Yan, Shuang Xiao, Min Chen, Liting LI, Miao Wei, Huafeng Duo, Jia Cheng, Lingge Luo, Nana Sui, Yongfang Xu, Dan Yang, Chunyan Zhu, Lin Klein, Christian Wu, Depei |
| author_facet | Fu, Chengcheng LI, Chunrui Wang, DI Jin, Song Yao, Weiqin Shang, Jingjing Yan, Shuang Xiao, Min Chen, Liting LI, Miao Wei, Huafeng Duo, Jia Cheng, Lingge Luo, Nana Sui, Yongfang Xu, Dan Yang, Chunyan Zhu, Lin Klein, Christian Wu, Depei |
| author_sort | Fu, Chengcheng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430720 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104307202023-08-17 P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES Fu, Chengcheng LI, Chunrui Wang, DI Jin, Song Yao, Weiqin Shang, Jingjing Yan, Shuang Xiao, Min Chen, Liting LI, Miao Wei, Huafeng Duo, Jia Cheng, Lingge Luo, Nana Sui, Yongfang Xu, Dan Yang, Chunyan Zhu, Lin Klein, Christian Wu, Depei Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430720/ http://dx.doi.org/10.1097/01.HS9.0000972512.53497.1f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Fu, Chengcheng LI, Chunrui Wang, DI Jin, Song Yao, Weiqin Shang, Jingjing Yan, Shuang Xiao, Min Chen, Liting LI, Miao Wei, Huafeng Duo, Jia Cheng, Lingge Luo, Nana Sui, Yongfang Xu, Dan Yang, Chunyan Zhu, Lin Klein, Christian Wu, Depei P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title | P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title_full | P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title_fullStr | P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title_full_unstemmed | P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title_short | P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES |
| title_sort | p1406: safety and efficacy of ibi346, a first-in-class bcma-targeting modular car-t cell therapy, for patients with relapsed/refractory multiple myeloma (rrmm): preliminary results from two phase i studies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430720/ http://dx.doi.org/10.1097/01.HS9.0000972512.53497.1f |
| work_keys_str_mv | AT fuchengcheng p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT lichunrui p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT wangdi p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT jinsong p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT yaoweiqin p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT shangjingjing p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT yanshuang p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT xiaomin p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT chenliting p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT limiao p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT weihuafeng p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT duojia p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT chenglingge p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT luonana p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT suiyongfang p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT xudan p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT yangchunyan p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT zhulin p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT kleinchristian p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies AT wudepei p1406safetyandefficacyofibi346afirstinclassbcmatargetingmodularcartcelltherapyforpatientswithrelapsedrefractorymultiplemyelomarrmmpreliminaryresultsfromtwophaseistudies |